Ligand-specific differential regulation of 5-hydroxytryptamine receptors: Functional selectivity in serotonergic signaling

Wiley Interdisciplinary Reviews: Membrane Transport and Signaling

Volumn 1, Issue 4, 2012, Pages 453-466

  Stroth, Nikolas ^a   Svenningsson, Per ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PSYCHEDELIC AGENT; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN RECEPTOR;

AMINO ACID SUBSTITUTION; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; GENOTYPE; HUMAN; INTERNALIZATION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVIEW; RNA EDITING; SEROTONIN RELEASE; SIGNAL TRANSDUCTION;

EID: 84879194146     PISSN: 2190460X     EISSN: 21904618     Source Type: Journal    
DOI: 10.1002/wmts.39     Document Type: Review

References (78)

1. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 1995, 16:232-238.
2. Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther 2011, 336:296-302.
3. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov 2010, 9:373-386.
4. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 2007, 320:1-13.
5. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 1998, 54:94-104.
6. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 2003, 24:346-354.
7. Björk K, Svenningsson P. Modulation of monoamine receptors by adaptor proteins and lipid rafts: role in some effects of centrally acting drugs and therapeutic agents. Annu Rev Pharmacol Toxicol 2011, 51: 211-242.
8. Kenakin T. Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 2002, 1:103-110.
9. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 2010, 62:265-304.
10. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003, 55:597-606.
11. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull 2001, 56:441-451.
12. Smith NJ, Bennett KA, Milligan G. When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 2011, 331:241-247.
13. Roth BL, Chuang DM. Multiple mechanisms of serotonergic signal transduction. Life Sci 1987, 41:1051-1064.
14. Aghajanian GK, Sanders-Bush E. Serotonin. In: Neuropsychopharmacology-5th Generation of Progress. 5th ed. American College of Neuropsychopharmacology; 2008, 15-34.
15. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
16. Hannon J, Hoyer D. Molecular biology of 5-HT receptors. Behav Brain Res 2008, 195:198-213.
17. Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. Trends Pharmacol Sci 2008, 29:454-464.
18. Raote I, Bhattacharya A, Panicker MM. Serotonin 2A (5-HT2A) Receptor Function: Ligand-Dependent Mechanisms and Pathways; 2007.
19. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE. Insights into G protein structure, function, and regulation. Endocr Rev 2003, 24:765-781.
20. Marty C, Ye RD. Heterotrimeric G protein signaling outside the realm of seven transmembrane domain receptors. Mol Pharmacol 2010, 78:12-18.
21. Patel TB. Single transmembrane spanning heterotrimeric g protein-coupled receptors and their signaling cascades. Pharmacol Rev 2004, 56:371-385.
22. Lanfumey L, Hamon M. 5-HT1 receptors. Curr Drug Targets CNS Neurol Disord 2004, 3:1-10.
23. Gettys TW, Fields TA, Raymond JR. Selective activation of inhibitory G-protein α-subunits by partial agonists of the human 5-HT1A receptor. Biochemistry 1994, 33:4283-4290.
24. Newman-Tancredi A, Cussac D, Marini L, Millan MJ. Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Gα(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Mol Pharmacol 2002, 62:590-601.
25. Newman-Tancredi A, Conte C, Chaput C, Verriele L, Millan MJ. Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor: G-protein stoichiometry. Neuropharmacology 1997, 36:451-459.
26. Heusler P, Pauwels PJ, Wurch T, Newman-Tancredi A, Tytgat J, Colpaert FC, Cussac D. Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling. Neuropharmacology 2005, 49: 963-976.
27. Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, et al. Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. Br J Pharmacol 2009, 156:338-353.
28. Mannoury La, Cour C, Mestikawy El, Hanoun S, Hamon N, Lanfumey L. Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol Pharmacol 2006, 70: 1013-1021.
29. Valdizan EM, Castro E, Pazos A. Agonist-dependent modulation of G-protein coupling and transduction of 5-HT1A receptors in rat dorsal raphe nucleus. Int J Neuropsychopharmacol 2010, 13:835-843.
30. Lin SL, Setya S, Johnson-Farley NN, Cowen DS. Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family. Br J Pharmacol 2002, 136:1072-1078.
31. Newman-Tancredi A, Cussac D, Marini L, Touzard M, Millan MJ. h5-HT(1B) receptor-mediated constitutive Gαi3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. Br J Pharmacol 2003, 138:1077-1084.
32. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci 1995, 16:256-258.
33. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004, 24: 3235-3241.
34. Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Pharmacol Exp Ther 2007, 321:1054-1061.
35. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE. Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 2003, 304:229-237.
36. Kurrasch-Orbaugh DM, Parrish JC, Watts VJ, Nichols DE. A complex signaling cascade links the serotonin2A receptor to phospholipase A2 activation: the involvement of MAP kinases. J Neurochem 2003, 86:980-991.
37. Nichols DE. Hallucinogens. Pharmacol Ther 2004, 101:131-181.
38. Glennon RA. Animal models for assessing hallucinogenic agents. Neuromethods 1993, 24:345-381.
39. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 2003, 23: 8836-8843.
40. Halberstadt AL, Geyer MA. LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT(2A) receptor. Psychopharmacology (Berl) 2010, 208:179-189.
41. Manning DR. Measures of efficacy using G proteins as endpoints: differential engagement of G proteins through single receptors. Mol Pharmacol 2002, 62: 451-452.
42. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 2007, 53:439-452.
43. Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A 2008, 105:1079-1084.
44. Schmid CL, Bohn LM. Serotonin, but not N-methyl tryptamines, activates the serotonin 2A receptor via a β-arrestin2/Src/Akt signaling complex in vivo. J Neurosci 2010, 30:13513-13524.
45. Willins DL, Alsayegh L, Berry SA, Backstrom JR, Sanders-Bush E, Friedman L, Khan N, Roth BL. Serotonergic antagonist effects on trafficking of serotonin 5-HT2A receptors in vitro and in vivo. Ann N Y Acad Sci 1998, 861:121-127.
46. Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, Roth BL. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 2001, 276:8269-8277.
47. Hanley NR, Hensler JG. Mechanisms of ligand-induced desensitization of the 5-hydroxytryptamine(2A) receptor. J Pharmacol Exp Ther 2002, 300:468-477.
48. Schlag BD, Lou Z, Fennell M, Dunlop J. Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J Pharmacol Exp Ther 2004, 310:865-870.
49. Yadav PN, Kroeze WK, Farrell MS, Roth BL. Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 2011, 339:99-105.
50. Brea J, Castro M, Giraldo J, Lopez-Gimenez JF, Padin JF, Quintian F, Cadavid MI, Vilaro MT, Mengod G, Berg KA, et al. Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol Pharmacol 2009, 75:1380-1391.
51. Urizar E, Yano H, Kolster R, Gales C, Lambert N, Javitch JA. CODA-RET reveals functional selectivity as a result of GPCR heteromerization. Nat Chem Biol 2011, 7:624-630.
52. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 2004, 66:1-7.
53. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 1997, 387:303-308.
54. Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem 1999, 274: 9472-9478.
55. Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol 1999, 55:863-872.
56. Stout BD, Clarke WP, Berg KA. Rapid desensitization of the serotonin(2C) receptor system: effector pathway and agonist dependence. J Pharmacol Exp Ther 2002, 302:957-962.
57. Price RD, Weiner DM, Chang MS, Sanders-Bush E. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem 2001, 276:44663-44668.
58. Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ. Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 2002, 62:578-589.
59. Backstrom JR, Chang MS, Chu H, Niswender CM, Sanders-Bush E. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD). Neuropsychopharmacology 1999, 21:77S-81S.
60. Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol 2008, 594:32-38.
61. Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP. A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin2C receptor alters both ligand-dependent and -independent receptor signaling. J Pharmacol Exp Ther 2008, 324: 1084-1092.
62. Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. Br J Pharmacol 2001, 134:386-392.
63. Englander MT, Dulawa SC, Bhansali P, Schmauss C. How stress and fluoxetine modulate serotonin 2C receptor pre-mRNA editing. J Neurosci 2005, 25:648-651.
64. Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron 2002, 34:349-356.
65. Werry TD, Gregory KJ, Sexton PM, Christopoulos A. Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 2005, 93:1603-1615.
66. Knauer CS, Campbell JE, Chio CL, Fitzgerald LW. Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:461-471.
67. Strachan RT, Sciaky N, Cronan MR, Kroeze WK, Roth BL. Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity. Mol Pharmacol 2010, 77: 327-338.
68. van Hooft JA, Vijverberg HP. Selection of distinct conformational states of the 5-HT3 receptor by full and partial agonists. Br J Pharmacol 1996, 117:839-846.
69. Kenakin T. Agonist-receptor efficacy. I: Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol Sci 1995, 16:188-192.
70. Krobert KA, Andressen KW, Levy FO. Heterologous desensitization is evoked by both agonist and antagonist stimulation of the human 5-HT(7) serotonin receptor. Eur J Pharmacol 2006, 532:1-10.
71. Schulte G, Levy FO. Novel aspects of G-protein-coupled receptor signalling-different ways to achieve specificity. Acta Physiol (Oxf) 2007, 190:33-38.
72. Fitzgerald LW, Conklin DS, Krause CM, Marshall AP, Patterson JP, Tran DP, Iyer G, Kostich WA, Largent BL, Hartig PR. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem 1999, 72:2127-2134.
73. Milligan G. High-content assays for ligand regulation of G-protein-coupled receptors. Drug Discov Today 2003, 8:579-585.
74. Berg KA, Clarke WP. Development of functionally selective agonists as novel therapeutic agents. Drug Discovery Today: Therapeutic Strategies 2006, 3:421-428.
75. Gurwitz D, Haring R. Ligand-selective signaling and high-content screening for GPCR drugs. Drug Discov Today 2003, 8:1108-1109.
76. Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL. Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol 2009, 76:710-722.
77. Berg KA, Harvey JA, Spampinato U, Clarke WP. Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 2008, 172:287-305.
78. Rosenzweig-Lipson S, Dunlop J, Marquis KL. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect 2007, 20:565-571.